C$34.76 0.4 1.2%
Last Trade - 16/04/21
| Market Cap | £7.57bn |
| Enterprise Value | £7.24bn |
| Revenue | £292.7m |
| Position in Universe | 61st / 2713 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Mar | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.37 | 12.7 | 39.9 | 77.9 | 226.3 | 398.8 | 557.4 | 796 | +178.7% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Canopy Growth Corp, formerly Tweed Marijuana Inc, is a Canada-based multi-brand cannabis company. The Company, through its subsidiaries Tweed Inc, Bedrocan Canada Inc, Tweed Farms Inc and Mettrum Health Corp is engaged in the business of producing and selling legal marijuana in the Canadian medical market. It is also focusing on producing and selling marijuana in the recreational market in Canada. Its core brands are Tweed and Bedrocan. Tweed is a licensed producer of medical marijuana. Tweed's commercial license covers approximately 168,000 square feet of its Smiths Falls facility and allows Tweed to produce and sell approximately 3,540 kilograms of medical marijuana per year. Tweed's built-out production capacity is over 10 climate controlled indoor growing rooms. Bedrocan is a medical-grade cannabis. Bedrocan's over 52,000 square feet production facility in Toronto, Ontario is licensed, and includes over 30 vegetative and growing rooms, and over three dispensing rooms.
| Last Annual | March 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | August 5, 2009 |
| Public Since | June 4, 2010 |
| No. of Shareholders: | n/a |
| No. of Employees: | 4,434 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | S&P/TSX Composite , S&P - Tse 300 Capped , |
| Exchange | Toronto Stock Exchange |
| Shares in Issue | 376,840,247 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 1 Hershey Dr, SMITHS FALLS, K7A 0A8, Canada |
| Web | https://www.canopygrowth.com/ |
| Phone | +1 613 5999600 |
| Contact | () |
| Auditors | KPMG LLP |
As of 16/04/21, shares in Canopy Growth are trading at C$34.76, giving the company a market capitalisation of £7.57bn. This share price information is delayed by 15 minutes.
Shares in Canopy Growth are currently trading at C$34.76 and the price has moved by 70.39% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Canopy Growth price has moved by 26.63% over the past year.
Of the analysts with advisory recommendations for Canopy Growth, there are there are currently 1 "buy" , 10 "hold" and 4 "sell" recommendations. The overall consensus recommendation for Canopy Growth is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Canopy Growth is scheduled to issue upcoming financial results on the following dates:
Canopy Growth does not currently pay a dividend.
Canopy Growth does not currently pay a dividend.
Canopy Growth does not currently pay a dividend.
To buy shares in Canopy Growth you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Canopy Growth are currently trading at C$34.76, giving the company a market capitalisation of £7.57bn.
Here are the trading details for Canopy Growth:
Based on an overall assessment of its quality, value and momentum, Canopy Growth is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Canopy Growth are currently priced at C$34.76. At that level they are trading at 18.15% discount to the analyst consensus target price of 0.00.
Analysts covering Canopy Growth currently have a consensus Earnings Per Share (EPS) forecast of -3.013 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Canopy Growth. Over the past six months, the relative strength of its shares against the market has been 24.74%. At the current price of C$34.76, shares in Canopy Growth are trading at 7.35% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Canopy Growth.
Canopy Growth's management team is headed by:
Here are the top five shareholders of Canopy Growth based on the size of their shareholding:
